9 results about "Clinical prognosis" patented technology

The application provides a model construction and verification method and nomogram for predicting the clinical prognosis of SFTS patients complicated with AP. By collecting the clinical data of SFTS patients, the independent risk factors related to adverse prognosis are screened out by using LASSO regression analysis, a multi-factor Logistic regression model is constructed, and the model is visualized by nomogram for predicting the adverse prognosis of SFTS patients complicated with AP. The model has high discrimination and calibration, and can provide an effective prediction tool for clinicians to optimize clinical decision-making.

The present application belongs to the technical field of biological medicine, and particularly relates to a human glioma DNA marker and application thereof. The marker comprises three DNAs, namely PBK, SPP1 and LTA, and the corresponding DNA nucleotide sequences are shown in SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3, respectively. The present application provides a molecular marker for glioma prognosis prediction and application thereof. The transcriptome dataset of glioma patients is obtained by TCGA, CGGA-array and CGGA-seq datasets, and three gene markers are screened. Research shows that the three gene markers can independently predict the survival of glioma patients, and can be used as a reference index for judging the survival time of glioma prognosis and predicting the survival risk. By studying the relationship between the three gene markers and the clinical prognosis of glioma patients, a new marker is provided for the prognosis of glioma, so as to improve the timely intervention treatment of glioma patients and improve the clinical prognosis of patients. It has very important significance in clinical practice.

This invention relates to the field of biomedical technology and provides an application of TAX1BP1 in the preparation of radiosensitizing drugs for glioma. This invention reveals for the first time the regulatory role of TAX1BP1 in the radiotherapy response of glioma, filling a research gap in the mechanism by which TAX1BP1 regulates tumor radiotherapy resistance, providing a new molecular target for radiosensitizing glioma, and solving the current problem of lacking highly efficient and specific sensitizing targets in glioma radiotherapy. The solution provided by this invention can be combined with existing radiotherapy regimens and is compatible with various intervention methods such as interfering RNA and antisense oligonucleotides, providing theoretical and experimental basis for the development of novel radiosensitizing drugs, and can effectively improve the clinical prognosis of glioma patients.

The application provides a multifunctional adsorbent and a preparation method and application thereof, and the multifunctional adsorbent comprises a carrier and a functional layer arranged on the outer layer of the carrier; the carrier is polystyrene-epoxy resin; the functional layer is composed of a first grafting layer and a second grafting layer, the first grafting layer is formed by reacting tryptophan with the epoxy group of the carrier, and the second grafting layer is formed by reacting polyacrylic acid with the acryloyl group introduced on the carrier. The multifunctional adsorbent can simultaneously adsorb FIB, LDL-C and key inflammatory factors in blood, so as to reduce the high coagulation state of blood, improve lipid metabolism and inhibit excessive inflammatory reaction, thereby providing an effective scheme which can significantly improve the clinical prognosis for CLTI patients who cannot accept blood revascularization.

This invention discloses a highly sensitive LCN2 detection kit and its preparation method for assessing the prognostic risk of patients with stress-induced cardiomyopathy. The kit contains a signal probe composed of rare-earth-doped upconversion nanoparticles and an LCN2-specific DNA aptamer, as well as a complementary oligonucleotide quenching probe with a quenching group. Its core principle is based on fluorescence resonance energy transfer regulated by competitive binding: when the target protein LCN2 is absent, the binding of the two probes leads to luminescence quenching; when LCN2 is present, they competitively bind to the aptamer and dissociate the quenching probe, thereby restoring upconversion luminescence. This homogeneous detection method effectively avoids the interference of autofluorescence in biological samples by utilizing near-infrared excitation. Combined with the high stability and specificity of the aptamer, it achieves a simple, rapid, highly specific, and ultra-sensitive quantitative detection of LCN2 protein in serum, providing a reliable tool for clinical prognostic assessment.

The application belongs to the field of biological detection and relates to a kind of establishment and clinical use for bladder cancer prognosis risk marker.The marker is composed of 23 mutant genes of AHNAK2,RYR2,USH2A,DCHS2,BRCA2,RP1L1,FBN2,ZFYVE26,ANK1,NCOR1,F8,WNK1,IGSF10,COL11A1,RANBP2,MED1,FANCM,MYO18B,ZNFX1,MROH2B,AUTS2,CNOT1,COL5A1.The application screens reliable and independent biomarker which can effectively predict the clinical prognosis of bladder patients.Provides a best mutant marker as potential prognostic biomarker and prediction model for combined chemotherapy response of bladder patients.

The present application relates to the fields of medicine, biotechnology and clinical critical medicine, and specifically discloses application of tauroursodeoxycholic acid or pharmaceutically acceptable salt, derivative or precursor thereof in preparation of a drug for improving intestinal barrier function and prognosis of a patient with sepsis. The present application discloses for the first time a molecular mechanism of TUDCA for protecting intestinal barrier function by regulating a signal axis of intestinal flora-Coriolic acids-PPARbeta-ILK, and TUDCA significantly improves the integrity of intestinal barrier by restoring intestinal flora balance, inhibiting generation of harmful metabolite Coriolic acids and activating the PPARbeta-ILK signal pathway. In the treatment of sepsis, TUDCA not only helps to repair the intestinal barrier, but also can improve the clinical prognosis of the patient, reduce the level of systemic inflammation, alleviate multiple organ failure caused by sepsis, and improve the survival rate, thereby providing a new strategy for the treatment of sepsis.

A multimodal clinical prognostic algorithm based on generative pre-training and gated attention is proposed. This algorithm utilizes the BioGPT pre-trained medical language model to semantically encode medical record text and encodes structured clinical data through linear mapping and self-attention mechanisms, obtaining textual and structured feature representations. A bidirectional cross-modal attention mechanism enables deep interaction between the two types of features, resulting in mutually reinforcing text-guided and structured-guided representations. A gated fusion layer dynamically learns modal weights and performs adaptive weighted fusion to generate a unified multimodal semantic representation. Finally, an adaptive risk projection head incorporating a fully connected network and Dropout is used to output the probability distribution of patient mortality risk categories within different time windows. This algorithm achieves deep semantic alignment and adaptive fusion of multimodal clinical data, improving the accuracy and interpretability of prognostic prediction.